Our findings, suggested first that PREP inhibition could be useful to reduce an exaggerated new blood vessels generation during intestinal diseases through VEGF/eNOS attenuation, and second that increased cells’ positivity of CD34, recognized as a key regulator of neovascularization process, seemed to be attenuated in mice treated with both doses (2.5 and 5 mg/kg) of KYP-2047. This evidence concerns the gene CD34 and intestinal disorder.